GlassScriptPhysician profile
Michael G Kingston
NPI 1174791610
$773.08
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $615 · 2022: $158.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155.00 | 2021-2022 | |
| Amgen INC. | $149.85 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.70 | 2022 | |
| Lilly USA, LLC | $55.40 | 2021 | |
| Esperion Therapeutics, INC. | $48.79 | 2021 | |
| Amarin Pharma, INC. | $45.25 | 2021-2022 | |
| Abbott Laboratories | $42.31 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $30.74 | 2021 | |
| Novo Nordisk INC | $26.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.64 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $22.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.04 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.88 | 2021 | |
| Pfizer INC. | $15.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.97 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $13.23 | 2021 | |
| Glaxosmithkline, LLC. | $12.30 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kingston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.